BPC-157 Banned by WADA: What Athletes Need to Know (2026 Update)
Why Is BPC-157 Banned by WADA?
WADA prohibits BPC-157 because it meets the agency's performance-enhancement criterion through tissue repair and angiogenesis, and because it is not an approved pharmaceutical anywhere. The compound falls under both the S0 non-approved substances category and the S2 peptide hormones, growth factors and related substances category, depending on jurisdiction interpretation. Prohibition is year-round, in and out of competition.
The WADA ban on BPC-157 tells you more about how the agency classifies compounds than it does about whether the compound is dangerous. WADA prohibits it on two grounds: it is not approved as a medicine in any signatory country (covered by S0), and it acts on tissue-repair pathways shared with other prohibited peptide growth factors (covered by S2). The mechanism that triggered inclusion is the same one that makes it medically interesting, accelerated tissue repair and angiogenesis (Sikiric et al., Curr Med Chem, 2023), which WADA considers to confer unfair competitive advantage.
The current WADA Prohibited List and its annual updates govern the position. If you compete in a sport that is a WADA signatory, that is the starting and ending point. The biology does not matter. The therapeutic intent does not matter. The compound is prohibited in-competition and out-of-competition.
This guide covers what the ban actually entails, who it affects, what WADA monitoring means for recreational researchers, and what competitive athletes need to know before making any decision about BPC-157.
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
What the WADA Classification Means
BPC-157 is captured by WADA under both Section S0 (Non-Approved Substances) and Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The prohibition is year-round, covering both in-competition and out-of-competition periods, based on BPC-157's tissue repair and angiogenic properties meeting WADA's performance enhancement criterion under Article 4.3 of the World Anti-Doping Code.
WADA's Prohibited List is updated annually, typically published on 1 October each year and effective from 1 January (WADA, 2025 Prohibited List). BPC-157 is captured by Section S0 because it is not licensed as a medicine in any WADA-signatory jurisdiction, and by Section S2 because it acts on cellular repair pathways shared with EPO, growth hormone peptides, and synthetic IGF-1 (Sikiric et al., J Physiol Pharmacol, 2018).
The classification is not a safety judgment. WADA does not prohibit compounds because they are dangerous. Article 4.3 of the World Anti-Doping Code specifies that a compound is prohibited when it meets two of three criteria: performance enhancement potential, health risk, or violation of the spirit of sport. BPC-157 meets the performance criterion through accelerated healing and angiogenesis (Sikiric et al., Curr Med Chem, 2023).
The prohibition applies year-round. This is an important distinction from some banned substances that are only restricted in-competition. BPC-157 cannot be used during training periods, recovery periods, or any point during a competitive season without triggering a violation.
Who the Ban Applies To
The ban applies to every athlete competing under a WADA-signatory sport federation, from Olympic and professional athletes down to national-level, masters, and age-group competitors. It does not apply to recreational athletes or those competing exclusively in non-WADA-affiliated events. If you are uncertain, contact your national sport federation directly.
The ban applies to any athlete competing under a sport federation that is a WADA signatory. This covers virtually all organised, competitive sport at any level, from Olympic and Paralympic athletes to national-level competitors in affiliated federations, and in many cases masters and age-group competitors in WADA-signatory sports.
It does not apply to recreational athletes who do not compete, or who compete in non-WADA-affiliated events. A recreational runner using BPC-157 for injury recovery who does not compete in any sanctioned event is not in violation of any anti-doping rule. A masters marathon runner competing in a World Athletics-affiliated event is subject to the full WADA code.
If you are uncertain whether your sport or competition is WADA-governed, contact your national sport federation directly. Ignorance of prohibited status is not a valid defence in anti-doping proceedings.
| User Type | BPC-157 Status Under WADA | Notes |
|---|---|---|
| Olympic and professional athletes | PROHIBITED (in and out of competition) | Full WADA code; risk of multi-year ban |
| National-level competitors (WADA sport) | PROHIBITED | Same code applies at all levels |
| Masters / age-group competitors (WADA sport) | PROHIBITED | Most federations extend the code to masters divisions |
| Recreational, non-competitive | Permitted (research compound) | No WADA jurisdiction; check local law |
| Competitors in non-WADA events | Permitted under WADA code | Verify individual event rules before use |
What WADA Monitoring Means for Recreational Athletes
WADA monitoring and WADA prohibition are different things. The Monitoring Program tracks substances of interest that are not yet prohibited, helping the agency decide whether to ban them in future. Prohibition is enforceable; monitoring is observational. For recreational athletes outside WADA jurisdiction, neither status changes the legal or biological discussion of BPC-157.
One of the most common misreadings of WADA classifications is conflating the WADA Monitoring Program with the Prohibited List. The two are distinct. Substances on the Monitoring Program are tracked through anti-doping samples to inform WADA's decisions about future prohibition; they are not prohibited at the time of monitoring. Prohibited List substances, by contrast, trigger sanctions on detection.
BPC-157 sits on the Prohibited List. Its inclusion was preceded by a period under monitoring as WADA gathered prevalence and detection data. The transition from Monitoring Program to Prohibited List is a structured process described in the World Anti-Doping Code and updated annually (WADA Prohibited List landing page).
For recreational athletes, this distinction has practical implications:
- Monitoring is not prohibition. A substance under WADA monitoring (not on the Prohibited List) carries no anti-doping sanction. BPC-157 has moved beyond monitoring into full prohibition for WADA-tested athletes; recreational researchers are unaffected by either status.
- WADA jurisdiction does not extend to recreational sport. Anti-doping rules apply only to athletes registered under a WADA-signatory federation. A gym member, recreational runner, or non-competitive lifter is outside WADA jurisdiction entirely.
- The legal and biological questions remain separate. WADA classification does not determine what is legal in your country, what is safe, or what is biologically appropriate. Those questions answer to different frameworks: national pharmaceutical regulation, individual clinical context, and the research literature respectively.
- Sourcing and quality still matter. Whether or not you compete, the practical questions of supplier reliability, third-party Certificates of Analysis, and protocol design apply. A WADA-irrelevant researcher still benefits from research-grade product and an evidence-based protocol.
The short version: monitoring and prohibition are different regulatory states, both irrelevant to recreational athletes, and neither changes the underlying biological discussion of the compound.
Detection: What Athletes Need to Know
BPC-157 detection capability has improved significantly through mass spectrometry methods developed by WADA-accredited laboratories. The assumption that BPC-157 is undetectable is outdated. No standardised detection window exists, and metabolite detection may extend well beyond the compound's short plasma half-life, making any clearance time estimate unreliable for competitive athletes.
BPC-157 is challenging to detect with standard urine immunoassay testing. It is a short peptide with a very short plasma half-life (minutes in circulation), which makes direct detection of the parent compound difficult with conventional methods.
However, WADA-accredited laboratories have developed and continue to develop mass spectrometry methods capable of detecting peptides at low concentrations in urine and blood samples (WADA Accredited Laboratories). The detection capability for BPC-157 specifically has improved, and the assumption that it is "undetectable" is outdated and unreliable.
Detection windows
Published detection windows for BPC-157 in anti-doping literature are not standardised in the same way as more established prohibited substances. The practical position for any WADA-tested athlete is that the detection window is unknown and potentially extends beyond the biological half-life of the compound through metabolite detection. Treating any detection window estimate as reliable protection is a significant risk.
The Biological Passport
WADA's Athlete Biological Passport (ABP) tracks biomarker profiles over time. While BPC-157 itself may not trigger direct detection, secondary effects (changes in haematological or endocrine markers associated with accelerated tissue repair) could contribute to an atypical profile in athletes subject to longitudinal monitoring. This is a secondary risk that most discussions of BPC-157 detection overlook.
Therapeutic Use Exemptions
No Therapeutic Use Exemption pathway exists for BPC-157 because it is not an approved pharmaceutical in any WADA-signatory jurisdiction. TUEs require the compound to be a licensed medicine with documented medical applications. BPC-157 is classified as a research peptide, which categorically disqualifies it from exemption regardless of the therapeutic rationale.
A Therapeutic Use Exemption (TUE) allows a WADA-tested athlete to use a prohibited substance for a legitimate medical need. TUEs are granted for approved pharmaceuticals where the medical need is documented and no permitted alternative exists.
BPC-157 is not an approved pharmaceutical in any jurisdiction that is a WADA signatory. It is sold as a research compound, not a licensed medicine. This means no TUE pathway exists for BPC-157. An athlete cannot obtain a legitimate exemption for its use, regardless of the medical rationale.
This distinguishes BPC-157 from, for example, therapeutic testosterone (see our guide on BPC-157 and testosterone cypionate) or certain corticosteroids, which have established TUE pathways because they exist as licensed pharmaceutical products with documented medical applications and regulatory approval.
Practical Position for Competitive Athletes
The position is unambiguous: complete avoidance. BPC-157 is prohibited year-round, no TUE is available, detection methods are advancing, and a positive test carries a minimum two-year ban under the current WADA Code. Anti-doping testing occurs both in and out of competition, with registered testing pool athletes subject to no-notice testing at any time.
The position is unambiguous: if you are subject to WADA rules, BPC-157 is prohibited, no exemption is available, detection capability is improving, and a positive test carries a minimum two-year ban under the current WADA Code, with potential lifetime bans for aggravated violations or repeat offences.
The risk calculation is not about whether BPC-157 is likely to be tested for in any specific competition. Anti-doping testing is conducted both in and out of competition, and whereabouts requirements for registered testing pools mean elite athletes can be tested without notice at any time. The safest position for any WADA-tested athlete is complete avoidance.
For athletes who have sustained injuries and are researching recovery options, the appropriate pathway is physiotherapy, approved pharmacological interventions (where relevant), and working with team medical staff on WADA-compliant protocols.
Always work with a qualified clinician or sports medicine physician familiar with anti-doping regulations before using any compound during a competitive career.
Non-Competitive Use: A Different Framework
For non-competitive athletes and recreational researchers, the WADA Prohibited List carries no legal force. The relevant considerations shift entirely to the biological: mechanism of action, safety profile, protocol design, and sourcing quality. The regulatory ban and the research discussion are separate questions with separate answers that should not be conflated.
For athletes who do not compete in WADA-governed sport, the regulatory picture is entirely different. The WADA Prohibited List has no legal force for recreational athletes, gym-goers, or those competing in non-affiliated events. The relevant considerations shift to the biological and practical: mechanism, safety profile, protocol design, and sourcing quality.
Non-competitive researchers using BPC-157 for injury recovery operate outside the anti-doping framework entirely. Their decision is informed by the research literature, individual health context, and clinical guidance, not regulatory compliance. Many explore how BPC-157 compares to TB-500 as part of that research.
This distinction is worth stating clearly because much of the online discussion about BPC-157 conflates the regulatory position (relevant to competitive athletes) with the research and safety discussion (relevant to everyone). They are separate questions with separate answers.
References
- World Anti-Doping Agency. The Prohibited List. Annual update. wada-ama.org/en/prohibited-list
- World Anti-Doping Agency. Accredited Laboratories Network. wada-ama.org/en/who-we-are/laboratories
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. J Physiol Pharmacol. 2018. PMC6271067
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of various organ damage. Curr Med Chem. 2023. PMC12313605
- World Anti-Doping Code. Article 4.3, Criteria for Including Substances and Methods on the Prohibited List. World Anti-Doping Code
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
Share this article
Frequently Asked Questions
When was BPC-157 added to the WADA prohibited list?
BPC-157 entered WADA's regulatory framework progressively over recent years. It was tracked under the WADA Monitoring Program before being captured by the Prohibited List under Section S0 (Non-Approved Substances) and Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The Prohibited List is updated annually, typically published on 1 October and effective from 1 January, so the precise framing of BPC-157's inclusion depends on which year's list is referenced. The 2025 Prohibited List remains the current version of record at the time of writing.
Is BPC-157 banned by WADA or USADA?
Both. USADA enforces the WADA Code on behalf of the United States Anti-Doping Agency for athletes governed by US Olympic and Paralympic federations. The Prohibited List is the same document under both. BPC-157 is prohibited under the WADA framework, which means it is also prohibited under USADA's jurisdiction, UKAD, ASADA, and every other national anti-doping organisation that signs the World Anti-Doping Code. Athletes governed by any WADA-signatory body face identical restrictions on BPC-157.
Can BPC-157 be detected in anti-doping tests?
Yes. While BPC-157 has historically been difficult to detect with standard immunoassay urine tests due to its short plasma half-life, WADA-accredited laboratories have developed mass spectrometry methods capable of detecting it. Detection capability is improving and any assumption that BPC-157 is reliably undetectable should be treated as outdated and unreliable.
What happens if an athlete tests positive for BPC-157?
A positive test for a prohibited substance under the WADA Code typically results in a minimum two-year suspension for a first violation. Aggravating circumstances can increase this to four years or a lifetime ban. The athlete is responsible for any substance found in their body, regardless of how it got there or what their intent was. This is the strict liability principle under the WADA Code.
Can I get a Therapeutic Use Exemption for BPC-157?
No. TUEs are only granted for approved pharmaceutical products with documented medical uses and regulatory approval. BPC-157 is sold as a research compound and is not a licensed medicine in any WADA-signatory country. There is no TUE pathway available for it, regardless of the medical justification.
What should a competitive athlete use instead of BPC-157 for injury recovery?
WADA-compliant injury recovery relies on physiotherapy, approved pharmaceutical interventions where indicated, load management, sleep and nutrition optimisation, and evidence-based supplementation (creatine, collagen, omega-3s). Working with a sports medicine physician who is familiar with anti-doping regulations is the appropriate approach for competitive athletes managing significant injuries.
Read Next
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.